JP2023542291A5 - - Google Patents

Info

Publication number
JP2023542291A5
JP2023542291A5 JP2023515680A JP2023515680A JP2023542291A5 JP 2023542291 A5 JP2023542291 A5 JP 2023542291A5 JP 2023515680 A JP2023515680 A JP 2023515680A JP 2023515680 A JP2023515680 A JP 2023515680A JP 2023542291 A5 JP2023542291 A5 JP 2023542291A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
day
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542291A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075021 external-priority patent/WO2022053657A1/en
Publication of JP2023542291A publication Critical patent/JP2023542291A/ja
Publication of JP2023542291A5 publication Critical patent/JP2023542291A5/ja
Pending legal-status Critical Current

Links

JP2023515680A 2020-09-10 2021-09-10 びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 Pending JP2023542291A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076765P 2020-09-10 2020-09-10
US63/076,765 2020-09-10
PCT/EP2021/075021 WO2022053657A1 (en) 2020-09-10 2021-09-10 Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma

Publications (2)

Publication Number Publication Date
JP2023542291A JP2023542291A (ja) 2023-10-06
JP2023542291A5 true JP2023542291A5 (cg-RX-API-DMAC7.html) 2024-09-18

Family

ID=77914294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515680A Pending JP2023542291A (ja) 2020-09-10 2021-09-10 びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体

Country Status (11)

Country Link
US (2) US20230355753A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210744A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542291A (cg-RX-API-DMAC7.html)
KR (1) KR20230066581A (cg-RX-API-DMAC7.html)
CN (1) CN116782933A (cg-RX-API-DMAC7.html)
AU (1) AU2021339006A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004296A2 (cg-RX-API-DMAC7.html)
CA (1) CA3192255A1 (cg-RX-API-DMAC7.html)
IL (1) IL301102A (cg-RX-API-DMAC7.html)
MX (1) MX2023002542A (cg-RX-API-DMAC7.html)
WO (1) WO2022053657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102813816B1 (ko) * 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
JP2023542290A (ja) 2020-09-10 2023-10-06 ジェンマブ エー/エス 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2024236031A1 (en) 2023-05-15 2024-11-21 Genmab A/S Highly purified epcoritamab compositions

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2008145141A1 (en) 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
BR112016000666A2 (pt) 2013-07-12 2017-10-03 Zymeworks Inc Constructos de ligação de antígeno cd3 e cd19 biespecíficos
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
CN107660214B (zh) * 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
US20160199399A1 (en) 2015-01-09 2016-07-14 Medical Prognosis Institute A/S Methods for predicting drug responsiveness in cancer patients
CN104922688A (zh) 2015-02-10 2015-09-23 昆明贵研药业有限公司 奥沙利铂的环糊精复合物及制备方法
CN104829730A (zh) * 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
WO2017210485A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
EP3541843A1 (en) 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2018259078B2 (en) 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
BR112020015052A2 (pt) 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
EP4427810A3 (en) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
AU2020328195A1 (en) * 2019-08-15 2022-03-03 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses
KR20230008775A (ko) * 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2023542290A (ja) 2020-09-10 2023-10-06 ジェンマブ エー/エス 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
BR112023004319A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma difuso de grandes células b
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体

Similar Documents

Publication Publication Date Title
JP2023542290A5 (cg-RX-API-DMAC7.html)
JP2023541860A5 (cg-RX-API-DMAC7.html)
JP2023542289A5 (cg-RX-API-DMAC7.html)
JP2023541858A5 (cg-RX-API-DMAC7.html)
JP2023542092A5 (cg-RX-API-DMAC7.html)
JP2025016606A5 (cg-RX-API-DMAC7.html)
JP2023524149A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2020504723A5 (cg-RX-API-DMAC7.html)
JP2023123627A5 (cg-RX-API-DMAC7.html)
JP2011506483A5 (cg-RX-API-DMAC7.html)
JP7766392B2 (ja) 治療用抗cd40リガンド抗体
JP2021514973A5 (cg-RX-API-DMAC7.html)
RU2007137102A (ru) Способы лечения боли, вызванной остеоартритом, путем введения антагониста фактора роста нервов и содержащих его композиции
JP2020503260A5 (cg-RX-API-DMAC7.html)
CN106795219A (zh) 抗il‑17抗体及其生产和使用的方法
JP2021512107A5 (cg-RX-API-DMAC7.html)
RU2017120358A (ru) Анти-il-1-бета антитела и способы их применения
JP7702428B2 (ja) 抗glp1rアンタゴニスト抗体およびその使用方法
JP2017534646A5 (cg-RX-API-DMAC7.html)
JP2019517540A5 (cg-RX-API-DMAC7.html)
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2022512875A5 (cg-RX-API-DMAC7.html)
JP2023515675A5 (cg-RX-API-DMAC7.html)
RS57708B1 (sr) Antigen vezujući proteini specifični za p komponentu amiloida seruma